Business Context and Reporting Period
This Form 8-K Current Report was filed by AmerisourceBergen Corporation (now known as Cencora, Inc.) on November 11, 2010. The filing addresses a significant executive leadership change within the registrant.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel appointments rather than financial performance.
Material Changes
The primary material change reported is the appointment of Steven H. Collis as President and Chief Operating Officer (COO), effective November 11, 2010. Key details include:
- Role Expansion: Mr. Collis now oversees all business units, including AmerisourceBergen Drug Corporation, Specialty Group, Consulting Services, and Packaging Group.
- Leadership Restructuring: Prior to this appointment, Chief Executive Officer R. David Yost held the title of President. Mr. Collis will report directly to Mr. Yost.
- Employment Agreement: A Second Amendment and Restatement of Employment Agreement was executed, broadening non-compete obligations to cover a two-year period post-employment and restricting competition in any business reviewed by the Board for development or divestiture.
Guidance, Outlook, and Risks
The filing contains no financial guidance, market outlook, or discussion of general business risks. The primary contingency noted is the legal restriction on Mr. Collis's future employment activities via the updated non-compete clause.
Investor Verification Checklist
- Verify the effective date of Steven H. Collis's appointment as President and COO (November 11, 2010).
- Confirm the scope of Mr. Collis's new non-compete obligations, specifically the two-year post-employment restriction.
- Review the reporting structure change where the CEO no longer holds the President title.
- Note that this filing does not contain financial data; refer to the most recent 10-Q or 10-K for financial metrics.